The Torres-Ayuso laboratory conducts basic and translational research focused on (1) identifying new therapeutic targets, primarily protein kinases, and (2) overcoming mechanisms of therapy resistance in lung and head and neck cancers, specifically, squamous cell carcinomas (LSCC and HNSCC). Our scientific mission is to advance new precision medicine strategies, also known as targeted therapies, in LSCC and HNSCC.

To achieve this, we use functional genomics and genetic screens to identify novel kinase drivers in LSCC and HNSCC. We then apply a variety of molecular techniques – such as CRISPR interference, CRISPR, and shRNA – and phenotypic assays, to assess whether targeting these kinases prevents cancer cell proliferation, differentiation, and migration. We also employ proteomics and chemical biology approaches to determine how these kinases contribute to tumorigenesis and/or therapy resistance. Finally, we conduct efficacy studies in preclinical models of LSCC and HNSCC, including patient-derived xenografts, to assess the potential of targeting these kinase drivers, alone or in combination with standard of care.

To support our mission, the lab collaborates closely with other scientists and clinicians at Temple University, Fox Chase Cancer Center, and The Wistar Institute.